EMA’s Post-Brexit Home ‘Could Be Decided This Year’
The leader of Denmark’s bid to host the European Medicines Agency after the UK leaves the EU says that a rapid decision-making process on the agency’s new location is needed in order to avoid entanglements with the wider Brexit negotiations, and that a decision could be taken sometime in the second half of this year.
You may also be interested in...
Politics Could Get In Way Of Quick Decision On New EMA Home
An early decision on the new home for the European Medicines Agency would help to minimize the level of disruption that will be involved in moving the agency from London to somewhere else in Europe when the UK leaves the EU. The EMA and the European Parliament have both called for quick resolution on this, but what you want is not always what you get.
Malta Bids For EMA, Citing Quality Of Life, Healthcare, And Small Pharma Industry
Malta has joined the ever-growing number of countries wanting to host the European Medicines Agency when it relocates from the UK post-Brexit. The European Commission has said new “technical issues” have been raised that will need to be addressed, and industry bodies have outlined the criteria they say need to be met by the future host country.
Brexit And International Reference Pricing To Cost Companies Billions Of Dollars
Companies could lose hundreds of millions of dollars thanks to the impact of Brexit on international reference pricing. Brexit has other market access implications too, for example on the ebb and flow of parallel trade.